<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: We previously found that Nop-7-associated 2 (NSA2), which is involved in ribosomal biogenesis in yeast and is a putative cell cycle regulator in mammalian cells, is elevated in the kidney of Goto-Kakizaki (GK) rat, a spontaneous model of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Here we tested the hypothesis that elevated NSA2 is involved in diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (DN) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We examined Nsa2/NSA2 expression and NSA2 production in two <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> of <z:mp ids='MP_0002055'>diabetes</z:mp>, in cultured renal glomerular cells, and in diabetic patients with and without <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with <z:hpo ids='HP_0000112'>nephropathy</z:hpo> who had a history of <z:mp ids='MP_0002871'>albuminuria</z:mp> were further divided as responders (DN-NA; DN patients normoalbuminuric at the time of this study with a history of <z:mp ids='MP_0002871'>albuminuria</z:mp>) and non-responders (DN-A; diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> patients with <z:mp ids='MP_0002871'>albuminuria</z:mp>) to current treatment for <z:mp ids='MP_0002871'>albuminuria</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Renal Nsa2/NSA2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> increased in tandem with <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> in GK rats, in a <z:chebi fb="1" ids="9288">streptozotocin</z:chebi>-induced mouse model of <z:mp ids='MP_0002055'>diabetes</z:mp>, and in human mesangial cells (HMCs) grown in high <z:chebi fb="105" ids="17234">glucose</z:chebi> (p &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>In the mouse model of <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> resulted in increased Nsa2 expression and NSA2 levels in tubular and glomerular cells and in circulating cells; this increase was normalised by <z:mp ids='MP_0002055'>diabetes</z:mp> treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Circulating NSA2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels were elevated in patients with DN independently of body weight (BMI), glycaemic (HbA(1c)) and haemodynamic (blood pressure) control, and showed an inverse correlation with renal function (GFR, p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>NSA2 levels were the only variable that showed a significant difference between patients with <z:mp ids='MP_0002871'>albuminuria</z:mp> (DN-A) compared with non-albuminuric patients (DN-NA) and diabetic controls (p &lt; 0.05), this increase being independent of <z:hpo ids='HP_0000001'>all</z:hpo> other variables, including GFR </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: We show for the first time that renal and circulating NSA2/NSA2 levels are increased in <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> in experimental models of <z:mp ids='MP_0002055'>diabetes</z:mp>, and that circulating NSA2 is elevated in DN patients with <z:mp ids='MP_0002871'>albuminuria</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Further studies will be required to assess whether NSA2 plays a role in the pathogenesis of DN </plain></SENT>
</text></document>